Insulet's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Insulet's ROI in the second quarter of 2026?
Insulet Corporation achieved a return on average invested assets (ROI) of 14.3 % in its second quarter of 2026, this is above PODD's average return on investment of -6.59%.
Insulet Corporations investments during the 12 months ending in the second quarter of 2026 are valued at $2 billion

ROI has improved compared to 12.55% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 73 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 596 to 632.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-0.37 %	-7.84 %	7.06 %	12.48 %	20.52 %
Y / Y Net Income Change TTM	58.96 %	-24.71 %	-32.63 %	-7.48 %	25.19 %
Investment (TTM) in Millions	3,304	2,300	2,510	2,382	2,459
Return On Investment (TTM)	14.3 %	12.55 %	9.55 %	9.47 %	8.96 %
PODD's Overall Ranking	# 632	# 596	# 734	# 807	# 789
Seq. Investment Change TTM	8.75 %	-6.74 %	-0.47 %	-1.31 %	0.61 %
Seq. Net Income Change TTM	23.94 %	22.54 %	0.37 %	4.28 %	-41.3 %
Net Income (TTM) in Millions	375	303	247	246	236

PODD Company Profile >> Back to PODD Roi Comparisons >> See Annual PODD Return On Investment

Return On Investment PODD's Ranking
Within:	No.
Industry	# 18
Sector	# 74
Overall	# 632

Return On Investment Statistics
High	Average	Low
18.21 %	-6.59 %	-33.1 %
(Sep 30 2024)		(Mar 31 2016)

News about Insulet Corporation Return on Investment ROI

Insulet Corporation Appoints Ana Maria Chadwick as CFO, Marking a New Milestone in Financial Leadership

March 20, 2024

ACTON, Mass. - In a strategic move to strengthen its financial leadership, the global leader in tubeless insulin pump technology, Insulet Corporation (NASDAQ: PODD), has announced the appointment of Ana Maria Chadwick as Executive Vice President, Chief Financial Officer (CFO), and Treasurer. Chadwick will assume her new role effective April 22, 2024, signaling an exciting new chapter for the company.
The selection of Chadwick as CFO comes after an extensive search process conducted by Insulet Corporation, which sought an individual who could contribute to maintaining and expanding the company s success. With her extensive financial expertise and strategic insights, Chadwick is poised to play a pivotal role in driving the company s growth trajectory.

Insulet Corporation Strengthened with New Board Appointments and Retirements, Aims to Steer Financial Stability and Drive Growth

January 18, 2024

Insulet Announces Changes to Board of Directors with Retirements and New Appointments
ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is proud to announce significant changes to its Board of Directors. These changes, effective January 18, reflect the company s commitment to expert guidance and strategic leadership as it continues to revolutionize the healthcare industry.
Joining the esteemed board are Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories, and Timothy Stonesifer, Chief Financial Officer at Alcon Inc. Both industry leaders bring a wealth of experience and expertise to Insulet. Their appointments demonstrate the company s dedication to attracting top talent and strengthening its financial management capability.

Financial Statements
Insulet's II. Quarter Investments	$ 3,304 Millions	PODD's Balance sheet
Insulet's II. Quarter Income	$ 95 Millions	Quarterly PODD's Income Statement
PODD's Income by Division		See PODD's Income by Division

PODD Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	2,510	2,559	2,137	1,886	1,820
Y / Y Investment Growth	-1.91 %	19.76 %	13.28 %	3.65 %	9.3 %
Net Income in Millions	247	418	206	5	17
Y / Y Net Income Growth	-40.93 %	102.76 %	4384.78 %	-72.62 %	147.06 %
Annual Return On Investment	9.84 %	16.34 %	9.65 %	0.24 %	0.92 %

Annual Roi Comment

In the fiscal year 2025 ROI decreased relative to the previous year to 9.84 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PODD's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PODD's Competitors
Subscribers only: Roi for Insulet's Suppliers
Subscribers only: Return On Investment for PODD's Customers

Other Ratios
PODD's Roa	PODD's Inventory Turnover Ratio	PODD's Growth Rates	PODD's Dividend Statistics
	PODD's Profitability Ratios	PODD's Asset Turnover Ratio	PODD's Dividend Growth
PODD's Roe	PODD's Valuation Ratios	PODD's Financial Strength Ratios	PODD's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Tg Therapeutics Inc	39.26 %
Medpace Holdings Inc	35.54 %
Mettler toledo International Inc	34.41 %
Eli Lilly And Company	33.95 %
Acadia Pharmaceuticals Inc	31.05 %
Caredx Inc	29.42 %
Adma Biologics Inc	28.94 %
Protalix Biotherapeutics inc	25.72 %
Pro dex Inc	24.29 %
Innoviva Inc	23.33 %
Electromed Inc	23.18 %
Zevra Therapeutics Inc	22.90 %
Iradimed Corporation	22.57 %
Alnylam Pharmaceuticals Inc	22.10 %
Eton Pharmaceuticals Inc	21.31 %
Dexcom Inc	20.98 %
Healthcare Services Group Inc	20.93 %
Arcutis Biotherapeutics Inc	20.77 %
Chemed Corporation	20.13 %
Resmed Inc	20.01 %
Halozyme Therapeutics Inc	19.99 %
Vertex Pharmaceuticals Inc	19.97 %
Agilent Technologies inc	19.84 %
Illumina Inc	19.61 %
Puma Biotechnology Inc	19.60 %
United Therapeutics Corporation	19.53 %
Zoetis Inc	19.44 %
Krystal Biotech Inc	19.16 %
Carlisle Companies Incorporated	18.88 %
Neurocrine Biosciences Inc	17.51 %

Date modified: 2026-09-11T09:47:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.